The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A number of studies have shown that the quality of life of two common interstitial lung diseases (ild), sarcoidosis and pulmonary fibrosis patients, is impaired and that fatigue is a substantial problem for those patients. Furthermore, breathlessness is an additional major problem in pulmonary fibrosis. In the field of cardiovascular disease and breast cancer, personality factors have shown to play a role in patient's morbidity, mortality, quality of life, fatigue, depressive symptoms, and one study showed a predictive role of personality factors in health care consumption. No studies examining personality factors have been performed in sarcoidosis or pulmonary fibrosis. Therefore, the aim of the present study is to examine the role of personality factors as predictors of fatigue, quality of life, prognosis, and health care consumption in sarcoidosis and pulmonary fibrosis. In this study a number of possible moderators, such as social support, will also be examined, aiming to get a full picture of the relationship between the various factors examined. Known and new sarcoidosis and pulmonary fibrosis patients (inclusion period 1 year) of ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht will be asked to participate through completing questionnaires at baseline and every six months for 18 months, and allowing the researchers access to their medical records for the purpose of this study.
| Condition |
|---|
|
Sarcoidosis Pulmonary Fibrosis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | The Influence of Personality on Quality of Life, Fatigue, Prognosis, and Health Care Consumption in Pulmonary Fibrosis and Sarcoidosis |
| Enrollment: | 450 |
| Study Start Date: | August 2007 |
| Study Completion Date: | January 2009 |
| Groups/Cohorts |
|---|
|
sarcoidosis
Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
|
|
pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Sarcoidosis patients diagnosed according to WASOG guidelines and IPF patients diagnosed according ATS guidelines.
Inclusion Criteria:
- Patients have to be diagnosed with sarcoidosis based on consistent clinical features and BAL fluid analysis results, according to the WASOG guidelines.
- The diagnosis IPF will be made based on the ATS guidelines
Exclusion Criteria:
- Poor expression in the Dutch language
- Relevant co morbidity such as a malignancy, dementia, and a history of psychiatric illness
Contacts and Locations| Study Chair: | Marjolein Drent, Md, PhD | Maastricht University |
| Study Chair: | Jolanda de Vries, PhD | Tilburg University |
| Principal Investigator: | Marjon Elfferich, MSc | Gelderse Vallei Ziekenhuis Ede |
More Information
Publications:
| Responsible Party: | Maastricht University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00504621 History of Changes |
| Other Study ID Numbers: | MEC 07-4-015 |
| Study First Received: | July 19, 2007 |
| Last Updated: | April 5, 2012 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Maastricht University Medical Center:
|
personality fatigue quality of life health care consumption |
Additional relevant MeSH terms:
|
Fibrosis Pulmonary Fibrosis Sarcoidosis Pathologic Processes |
Lung Diseases Respiratory Tract Diseases Lymphoproliferative Disorders Lymphatic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013